Table 1 
Treatment of Ad vanced Melanoma Patients with Vaccine (1982-1992) 
Author 
Year 
Vaccine 
Preparation 
# of 
ZL&s. 
Results 
(Response) 
Weisenburger et al . 
8 
' 1982 
Allogeneic 
tumor cells, 
intralymphatic 
34 
Response in 9/34 
Q 
Cassel et al. 
1983 
Allogeneic 
oncolysates 
32 
Increased disease-free 
interval and survival 
Harris et al. 1 ^ 
1983 
Allogeneic 
tumor extract, 
CFA 
16 
Response in 1/16 
Calkins et al . ^ 
1984 
Allogeneic 44 
tumor cells, 
BCG, intralymphatic 
No Response 
1 7 
Humphrey et al. 
1984 
Allogeneic 
tumor homogenate 
84 
Increased disease-free 
interval and survival 
Morton et al. 1 ^ 
1986 
Allogeneic 
tumor cells, 
BCG 
140 
No effect 
Tallberg et al. 14 
1986 
Autologous 
tumor extract, 
polymerized, PPD 
6 
Increased disease-free 
interval and survival 
Hersey et al. 1 ^ 
1987 
Allogeneic 
viral oncolysate 
80 
Increased disease-free 
interval and survival 
Plager et al. 1 ^ 
1987 
Allogeneic 
viral oncolysate 
24 
No effect 
1 7 
Bystryn et al . 
1988 
Allogeneic 
tumor cell, 
soluble antigen, 
13 
alum 
Response in 1/13 
Berd and 
1 ft 
Mastrangelo 
1988 
Autologous 33 
tumor cells, 
with cyclophosphamide 
Response in 4/33 
Slingluff et al . ^ 
1988 
Allogeneic 
tumor cells, 
BCG 
1080 
Slightly increased 
survival 
Recombinant DNA Research, Volume 18 
[347] 
